Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
Malapelle U, Passiglia F, Pepe F, Pisapia P, Lucia Reale M, Cortinovis D, Fraggetta F, Galetta D, Garbo E, Graziano P, Pagni F, Pasello G, Piovano P, Pilotto S, Tiseo M, Genova C, Righi L, Troncone G, Novello S. Malapelle U, et al. Among authors: galetta d. Lung Cancer. 2024 May;191:107787. doi: 10.1016/j.lungcan.2024.107787. Epub 2024 Apr 5. Lung Cancer. 2024. PMID: 38593479 Free article.
Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G; Gruppo Oncologico Italia Meridionale. Gebbia V, et al. Among authors: galetta d. Lung Cancer. 2002 Aug;37(2):179-87. doi: 10.1016/s0169-5002(02)00076-4. Lung Cancer. 2002. PMID: 12140141 Clinical Trial.
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R. Garassino MC, et al. Among authors: galetta d. Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009. Epub 2010 Oct 15. Lung Cancer. 2011. PMID: 20950888 Clinical Trial.
Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens.
Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G, Spaggiari L, Papotti M, Barbareschi M, Graziano P, Decensi A, Cavazza A, Viale G. Pelosi G, et al. Among authors: galetta d. J Thorac Oncol. 2011 Jun;6(6):1039-49. doi: 10.1097/JTO.0b013e318211dd16. J Thorac Oncol. 2011. PMID: 21512408 Free article.
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, De Marinis F, Genestreti G, Crinò L, Grossi F, Caffo O, Ferraù F, Cruciani G, Brandes AA, Galetta D, Barni S, Fasola G, Cerea G, Ferrari S, Iannacone C, Ciardiello F. Gridelli C, et al. Among authors: galetta d. J Thorac Oncol. 2014 May;9(5):733-7. doi: 10.1097/JTO.0000000000000120. J Thorac Oncol. 2014. PMID: 24722160 Free article. Clinical Trial.
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; LIFE study team. Gridelli C, et al. Among authors: galetta d. J Cancer Res Clin Oncol. 2014 Oct;140(10):1783-93. doi: 10.1007/s00432-014-1715-2. Epub 2014 Jun 6. J Cancer Res Clin Oncol. 2014. PMID: 24903964 Free article.
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE Study Team. de Marinis F, et al. Among authors: galetta d. Clin Lung Cancer. 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.cllc.2014.04.004. Epub 2014 May 14. Clin Lung Cancer. 2014. PMID: 24925809 Free article.
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: d incecco a, galetta d. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice.
Novello S, Capelletto E, Cortinovis D, Tiseo M, Galetta D, Valmadre G, Casartelli C, Rapetti SG, Rossi A. Novello S, et al. Among authors: galetta d. Transl Lung Cancer Res. 2014 Jun;3(3):173-80. doi: 10.3978/j.issn.2218-6751.2014.06.10. Transl Lung Cancer Res. 2014. PMID: 25806297 Free PMC article.
326 results